394 related articles for article (PubMed ID: 33669072)
1. Targeting Epigenetic Regulators for Endometrial Cancer Therapy: Its Molecular Biology and Potential Clinical Applications.
Inoue F; Sone K; Toyohara Y; Takahashi Y; Kukita A; Hara A; Taguchi A; Tanikawa M; Tsuruga T; Osuga Y
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669072
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics in endometrial carcinogenesis - part 2: histone modifications, chromatin remodeling and noncoding RNAs.
Bartosch C; Lopes JM; Jerónimo C
Epigenomics; 2017 Jun; 9(6):873-892. PubMed ID: 28523964
[TBL] [Abstract][Full Text] [Related]
3. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Targets and their Inhibitors in Cancer Therapy.
Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
[TBL] [Abstract][Full Text] [Related]
5. Epigenomics in stress tolerance of plants under the climate change.
Kumar M; Rani K
Mol Biol Rep; 2023 Jul; 50(7):6201-6216. PubMed ID: 37294468
[TBL] [Abstract][Full Text] [Related]
6. [Lung cancer and its epigenetics association with chronic obstructive pulmonary disease].
Xu PW; Jin YT
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Feb; 30(1):70-3. PubMed ID: 23450484
[TBL] [Abstract][Full Text] [Related]
7. hMLH1 promoter methylation and silencing in primary endometrial cancers are associated with specific alterations in MBDs occupancy and histone modifications.
Xiong Y; Dowdy SC; Eberhardt NL; Podratz KC; Jiang SW
Gynecol Oncol; 2006 Oct; 103(1):321-8. PubMed ID: 16701802
[TBL] [Abstract][Full Text] [Related]
8. Noncoding RNAs involved in DNA methylation and histone methylation, and acetylation in diabetic vascular complications.
Lu J; Huang Y; Zhang X; Xu Y; Nie S
Pharmacol Res; 2021 Aug; 170():105520. PubMed ID: 33639232
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy.
Castilho RM; Squarize CH; Almeida LO
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28704968
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic mechanism of survivin dysregulation in human cancer.
Lyu H; Huang J; He Z; Liu B
Sci China Life Sci; 2018 Jul; 61(7):808-814. PubMed ID: 29318497
[TBL] [Abstract][Full Text] [Related]
11. Epigenetics in cancer: targeting chromatin modifications.
Ellis L; Atadja PW; Johnstone RW
Mol Cancer Ther; 2009 Jun; 8(6):1409-20. PubMed ID: 19509247
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
13. Prefrontal cortex expression of chromatin modifier genes in male WSP and WSR mice changes across ethanol dependence, withdrawal, and abstinence.
Hashimoto JG; Gavin DP; Wiren KM; Crabbe JC; Guizzetti M
Alcohol; 2017 May; 60():83-94. PubMed ID: 28433423
[TBL] [Abstract][Full Text] [Related]
14. Targeting epigenetic DNA and histone modifications to treat kidney disease.
Fontecha-Barriuso M; Martin-Sanchez D; Ruiz-Andres O; Poveda J; Sanchez-Niño MD; Valiño-Rivas L; Ruiz-Ortega M; Ortiz A; Sanz AB
Nephrol Dial Transplant; 2018 Nov; 33(11):1875-1886. PubMed ID: 29534238
[TBL] [Abstract][Full Text] [Related]
15. Relationship between DNA methylation, histone H4 acetylation and gene expression in the mouse imprinted Igf2-H19 domain.
Grandjean V; O'Neill L; Sado T; Turner B; Ferguson-Smith A
FEBS Lett; 2001 Jan; 488(3):165-9. PubMed ID: 11163765
[TBL] [Abstract][Full Text] [Related]
16. Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.
Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
Curr Pharm Des; 2017; 23(8):1167-1174. PubMed ID: 27774908
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Modification in Macrophages: A Promising Target for Tumor and Inflammation-associated Disease Therapy.
Sun P; Zhang SJ; Maksim S; Yao YF; Liu HM; Du J
Curr Top Med Chem; 2019; 19(15):1350-1362. PubMed ID: 31215380
[TBL] [Abstract][Full Text] [Related]
18. Targeting epigenetic regulations in cancer.
Ning B; Li W; Zhao W; Wang R
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):97-109. PubMed ID: 26508480
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic interplay between histone modifications and DNA methylation in gene silencing.
Vaissière T; Sawan C; Herceg Z
Mutat Res; 2008; 659(1-2):40-8. PubMed ID: 18407786
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic Treatment Options in Urothelial Carcinoma.
Pinkerneil M; Hoffmann MJ; Niegisch G
Methods Mol Biol; 2018; 1655():289-317. PubMed ID: 28889393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
